Published in Eur J Cancer on October 01, 1998
ABCC5, ERCC2, XPA and XRCC1 transcript abundance levels correlate with cisplatin chemoresistance in non-small cell lung cancer cell lines. Mol Cancer (2005) 1.49
Targeting and processing of site-specific DNA interstrand crosslinks. Environ Mol Mutagen (2010) 1.05
The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. Br J Cancer (2008) 1.02
Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil. Br J Cancer (2007) 0.93
Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity. Chembiochem (2011) 0.88
Decreased transcription-coupled nucleotide excision repair capacity is associated with increased p53- and MLH1-independent apoptosis in response to cisplatin. BMC Cancer (2010) 0.83
Functional evaluation of DNA repair in human biopsies and their relation to other cellular biomarkers. Front Genet (2014) 0.82
Functions of yeast helicase Ssl2p that are essential for viability are also involved in protection from the toxicity of adriamycin. Nucleic Acids Res (2004) 0.78
Roots of clinical resistance to STI-571 cancer therapy. Science (2001) 9.78
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst (2000) 2.06
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer (2001) 2.02
Apoptosis. Biochemical events and relevance to cancer chemotherapy. FEBS Lett (1992) 1.62
Tracheobronchial aspiration of foreign bodies: current indications for emergency plain chest radiography. Radiol Med (2006) 1.60
L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. Ann Oncol (1996) 1.52
Pain knowledge among doctors and nurses: a survey of 4912 healthcare providers in Tuscany. Minerva Anestesiol (2008) 1.44
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. Ann Oncol (1999) 1.42
Measurement of the sequence specificity of covalent DNA modification by antineoplastic agents using Taq DNA polymerase. Nucleic Acids Res (1991) 1.34
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A (2000) 1.34
Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol (2009) 1.31
Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer (2001) 1.31
p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res (1997) 1.31
Selective DNA interaction of the novel distamycin derivative FCE 24517. Cancer Res (1991) 1.31
Distamycins inhibit the binding of OTF-1 and NFE-1 transfactors to their conserved DNA elements. Nucleic Acids Res (1989) 1.28
Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer (1996) 1.27
In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas. Cancer Res (1987) 1.26
Distribution of paclitaxel within the nervous system of the rat after repeated intravenous administration. Neurotoxicology (2000) 1.25
L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. Ann Oncol (2000) 1.23
p21WAF1-derived peptides linked to an internalization peptide inhibit human cancer cell growth. Cancer Res (1997) 1.21
Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res (1998) 1.21
Cystic fibrosis: when should high-resolution computed tomography of the chest Be obtained? Pediatrics (1998) 1.18
High sodium intake is associated with increased glucocorticoid production, insulin resistance and metabolic syndrome. Clin Endocrinol (Oxf) (2013) 1.16
Cell cycle-related phosphatases CDC25A and B expression correlates with survival in ovarian cancer patients. Anticancer Res (2001) 1.13
Glutathione S-transferase activity in epithelial ovarian cancer: association with response to chemotherapy and disease outcome. Ann Oncol (1997) 1.12
Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis. Exp Cell Res (1998) 1.11
Differences in DNA damage produced by incorporation of 5-aza-2'-deoxycytidine or 5,6-dihydro-5-azacytidine into DNA of mammalian cells. Cancer Res (1986) 1.11
Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res (1994) 1.10
Accumulation of DNA strand breaks in cells exposed to methotrexate or N10-propargyl-5,8-dideazafolic acid. Cancer Res (1988) 1.10
Prevalence of feline immunodeficiency virus and other retroviral infections in sick cats in Italy. Vet Immunol Immunopathol (1992) 1.09
Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer (2006) 1.08
DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acids Res (1995) 1.08
Antiproliferative properties of flavone acetic acid (NSC 347512) (LM 975), a new anticancer agent. Eur J Cancer Clin Oncol (1987) 1.08
PARP1 is activated at telomeres upon G4 stabilization: possible target for telomere-based therapy. Oncogene (2010) 1.06
Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int J Cancer (1989) 1.05
Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Ann Oncol (1999) 1.04
Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer (2008) 1.03
Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer (1998) 1.02
Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol. J Bone Miner Res (2000) 1.01
Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer (2008) 1.00
Mode of action of thiocoraline, a natural marine compound with anti-tumour activity. Br J Cancer (1999) 1.00
Mitozolomide activity on human cancer cells in vitro. Br J Cancer (1986) 1.00
DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. Br J Cancer (1997) 0.99
Effect of Aplidin in acute lymphoblastic leukaemia cells. Br J Cancer (2003) 0.98
Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemother Pharmacol (1982) 0.98
Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res (1986) 0.98
Pulmonary manifestations of Gaucher disease: an increased risk for L444P homozygotes? Am J Respir Crit Care Med (1998) 0.97
Antiangiogenic activity of aplidine, a new agent of marine origin. Br J Cancer (2004) 0.97
Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer. Gynecol Oncol (1997) 0.97
Response to flavone acetic acid (NSC 347512) of primary and metastatic human colorectal carcinoma xenografts. Br J Cancer (1988) 0.97
Establishment of L1210 leukemia cells resistant to the distamycin-A derivative (FCE 24517): characterization and cross-resistance studies. Int J Cancer (1993) 0.96
Biochemical risk factors for cardiovascular disease in an aged male population: emerging vascular pathogens. Angiology (2001) 0.95
Cell cycle effects of gemcitabine. Int J Cancer (2001) 0.95
Effect of ecteinascidin-743 on the interaction between DNA binding proteins and DNA. Anticancer Drug Des (1999) 0.94
Distamycin A and tallimustine inhibit TBP binding and basal in vitro transcription. Nucleic Acids Res (1995) 0.94
Serum paraoxonase activity is decreased in uremic patients. Clin Chim Acta (1996) 0.94
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. Ann Oncol (2000) 0.94
ICRF 159 plus radiation versus radiation therapy alone in cervical carcinoma. A double-blind study. Oncology (1983) 0.94
The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71. Int J Oncol (2005) 0.94
Do anticancer agents reach the tumor target in the human brain? Cancer Chemother Pharmacol (1992) 0.93
In vivo studies with the novel anticancer agent mitozolomide (NSC 353451) on Lewis lung carcinoma. Cancer Chemother Pharmacol (1986) 0.93
Antitumor activity of the novel nitrosourea S10036 in rodent tumors. Anticancer Res (1989) 0.92
Cooperation between p53 and hMLH1 in a human colocarcinoma cell line in response to DNA damage. Clin Cancer Res (1999) 0.92
Early detection of lung involvement in lysinuric protein intolerance: role of high-resolution computed tomography and radioisotopic methods. Am J Respir Crit Care Med (1996) 0.91
Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Ann Oncol (1998) 0.91
Oral efficacy and bioavailability of a novel taxane. Clin Cancer Res (2000) 0.91
Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine. Br J Cancer (2002) 0.91
Pharmacokinetics of VM 26 given intrapericardially or intravenously in patients with malignant pericardial effusion. Cancer Chemother Pharmacol (1987) 0.91
Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. J Pharmacol Exp Ther (1994) 0.90
Total and free PSA serum concentrations are not influenced by extensive physical exercise and bicycle riding. Int J Sports Med (2005) 0.90
Phase I and clinical pharmacological evaluation of aphidicolin glycinate. J Natl Cancer Inst (1991) 0.90
Decreased half life of cyclophosphamide in patients under continual treatment. Eur J Cancer (1979) 0.90
DNA damage induced by alachlor after in vitro activation by rat hepatocytes. Toxicology (1992) 0.89
Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. A randomized clinical study. Cancer Chemother Pharmacol (1980) 0.89
Comparison of cell-cycle phase perturbations induced by the DNA-minor-groove alkylator tallimustine and by melphalan in the SW626 cell line. Int J Cancer (1995) 0.89
Renal involvement in feline immunodeficiency virus infection: a clinicopathological study. Nephron (1993) 0.89
In vitro cytotoxicity of GC sequence directed alkylating agents related to distamycin. J Med Chem (1993) 0.89
Low-dose oral etoposide in epithelial cancer of the ovary. Ann Oncol (1993) 0.88
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Ann Oncol (2006) 0.88
Mechanism of cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cells in vitro and modulation of the drug activity by folic or folinic acid. Br J Cancer (1994) 0.88
Nerve cell death induced in vivo by kainic acid and quinolinic acid does not involve apoptosis. Neuroreport (1991) 0.88
Dose-dependent pharmacokinetics of flavone acetic acid in mice. Cancer Chemother Pharmacol (1988) 0.88
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. Eur J Cancer (2009) 0.87
Development of distamycin-related DNA binding anticancer drugs. Expert Opin Investig Drugs (2001) 0.87
DNA cross-linking responses of human malignant glioma cell strains to chloroethylnitrosoureas, cisplatin, and diaziquone. Cancer Res (1987) 0.87
Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. Br J Cancer (1997) 0.87
Genetic instability influences drug response in cancer cells. Curr Drug Targets (2010) 0.87
Mismatch repair deficiency is associated with resistance to DNA minor groove alkylating agents. Br J Cancer (1999) 0.87
The enzyme glutathione peroxidase in arachidonic acid metabolism of human platelets. J Lab Clin Med (1984) 0.87
Human ovarian tumors in primary culture: growth, characterization and initial evaluation of the response to cis platinum treatment in vitro. Int J Cancer (1988) 0.87
A limited sampling model for the pharmacokinetics of etoposide given orally. Cancer Chemother Pharmacol (1993) 0.86
DNA-minor-groove alkylators, a new class of anticancer agents. Ann Oncol (1994) 0.86
Antitumor activity of taxol (NSC-125973) in human ovarian carcinomas growing in the peritoneal cavity of nude mice. Ann Oncol (1993) 0.86
Synchronisation of cancer cell lines of human origin using methotrexate. Cytometry (1990) 0.86
Proneness to UV-induced apoptosis in human fibroblasts defective in transcription coupled repair is associated with the lack of Mdm2 transactivation. Oncogene (2000) 0.86
Modulation of transcription factor--DNA interactions by anticancer drugs. Anticancer Drug Des (1994) 0.86
Phase I study of the antifolate N10-propargyl-5,8-dideazafolic acid, CB 3717. Eur J Cancer Clin Oncol (1988) 0.86